Novo Nordisk A/S (NYSE:NVO) Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 3.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 640,449 shares of the company's stock after selling 21,303 shares during the period. Sei Investments Co.'s holdings in Novo Nordisk A/S were worth $55,090,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in NVO. Center for Financial Planning Inc. grew its position in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Daiwa Securities Group Inc. purchased a new stake in shares of Novo Nordisk A/S in the third quarter worth about $28,000. Albion Financial Group UT grew its holdings in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after acquiring an additional 278 shares during the period. Sound Income Strategies LLC grew its holdings in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after acquiring an additional 243 shares during the period. Finally, Hager Investment Management Services LLC purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $46,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $1.55 during trading on Thursday, hitting $70.18. The company had a trading volume of 7,960,944 shares, compared to its average volume of 5,475,702. The firm has a market capitalization of $314.93 billion, a price-to-earnings ratio of 21.33, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The stock has a fifty day simple moving average of $82.78 and a two-hundred day simple moving average of $99.75. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a fifty-two week low of $69.78 and a fifty-two week high of $148.15.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's payout ratio is presently 47.72%.

Wall Street Analyst Weigh In

NVO has been the topic of several recent research reports. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.